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ABSTRACT
Introduction: Daptomycin is a cyclic
lipopeptide antibiotic, frequently administered
for Staphylococcus aureus bloodstream infections.
Numerous studies have shown that daptomycin
is relatively safe and well tolerated. Serious
adverse events possibly related to this
antimicrobial compound are rare. We report a
case of acute angioedema triggered by
daptomycin.
Case Report: A 60-year-old woman with S.
aureus bacteremia without identified source
was treated intravenously with high-dose
beta-lactams at our institution. Because S.
aureus bacteremia persisted on day 6, and in
parallel, acute kidney injury developed,
antimicrobial treatment was switched to a
combination therapy with daptomycin and
ceftriaxone. Shortly after completion of the
first daptomycin administration, the patient
developed lip and tongue swelling and
dyspnea. Acute angioedema was clinically
evident. Antibiotic therapy was switched to
vancomycin, and the further clinical course
was favorable. An intradermal test showed a
significant wheal diameter for daptomycin, but
negative results for ceftriaxone.
Conclusion: The association with daptomycin
in this case is either probable or certain.
Clinicians should be aware that daptomycin
can cause immediate-type hypersensitivity
reactions, including acute angioedema, even
upon first administration.
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
04D4F0603DE6E6DC.
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INTRODUCTION
Daptomycin is a cyclic lipopeptide antibiotic
approved for the treatment of complicated skin
and skin structure infections, as well as for
Staphylococcus aureus bloodstream infections,
including those occurring with right-sided
infective endocarditis [1, 2]. Data analyses
from the EU-CORE registry consisting of 6075
patients indicate that daptomycin is relatively
safe and well tolerated, even at high doses
([6 mg/kg/day) [3]. Serious adverse events
possibly related to daptomycin occurred in
B2% of patients, but hypersensitivity reactions
were rare [3]. The precise clinical manifestations
of these hypersensitivity reactions are not
described. These registry data are important, in
particular when facing a previously undescribed
adverse event to a compound. Here, we report a
case of acute angioedema triggered by
daptomycin.
CASE REPORT
A 60-year-old woman was admitted to our
hospital because of immobilizing lumbar back
pain and elevated inflammatory markers in
blood tests. Spine infection was suspected, and
after obtaining blood cultures, the patient was
treated empirical therapy with ceftriaxone (2 g
once daily). Growth of Gram-positive cocci was
detected in all blood culture samples.
Antimicrobial treatment was switched to
amoxicillin/clavulanate (2.2 g every 4 h on
days 3 and 4 of hospitalization), and then
streamlined to flucloxacillin (2 g every 4 h)
after identification of methicillin-susceptible S.
aureus. Despite 2 MRI scans, a PET-CT scan, an
anti-granulocyte scintigraphy and several
transesophageal echocardiographies, the
source of bacteremia was not identified. On
day 6, blood cultures were still positive for S.
aureus. Thus, persistent S. aureus bacteremia
without identified source was postulated. In
parallel, acute kidney injury developed. Because
of persistent bacteremia and renal impairment,
antimicrobial treatment was switched to a
combination therapy with daptomycin
(10 mg/kg body weight) and ceftriaxone (2 g
once daily) [4]. Shortly after completion of the
first daptomycin administration (60 min
infusion), the patient developed lip and
tongue swelling and dyspnea. After adrenaline
inhalation and intravenous administration of
clemastine and methylprednisolone, symptoms
and findings resolved. No skin eruption or
diffuse lymphadenopathy was noted in clinical
examinations, and results of laboratory
investigations showed no elevated eosinophil
counts, atypical lymphocytosis or increased
serum alanine aminotransferase. Thus, the
differential diagnosis of drug reaction with
eosinophilia and systemic symptoms (DRESS)
appeared unlikely, and a diagnosis of acute
angioedema was made.
Antibiotic therapy was switched to
vancomycin and continued for 4 weeks. Doses
were adapted according to the gradually
recovering renal function, and monitored by
vancomycin trough levels in serum. Blood
cultures showed no growth on day 9 and
results remained negative on day 12. The
further clinical course was favorable.
The workup of the case included
investigations into the cause of angioedema
and renal failure. The timely occurrence of the
latter and the histopathological characteristics
of the kidney biopsy result were consistent with
acute interstitial nephritis [5]. High-dose
beta-lactam exposure during the first 4–6 days
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of hospitalization was considered the most
likely cause.
After intermittent hemodialysis (days 10–19)
and corticosteroid treatment, renal function
values returned to normal on the day of
discharge (day 32).
A detailed review of the drug charts strongly
suggested a timely association between
angioedema and daptomycin. The role of other
compounds (nonsteroidal anti-inflammatory
drugs, opioids) in causing direct histamine
release or immunoglobulin E (IgE)-mediated
reaction was also reviewed. These compounds
were repeatedly challenged without an obvious
clinical reaction. Because no similar case was
previously described in the literature, the
differential diagnosis included a more
commonly known reaction to ceftriaxone,
although exposure to ceftriaxone in the
preceding week spoke against such a reaction.
Also, the workup of the patient’s history revealed
that she was exposed to 1st and 2nd generation
cephalosporins in the previous years without any
notable reaction. Daptomycin re-exposure was
considered in the intensive care unit (ICU). An
intradermal test (IDT) was performed first. The
results were positive for daptomycin (5 mg/mL,
wheal diameter 5 mm after 20 min), but negative
for ceftriaxone (2 mg/mL). One healthy control
produced no reaction to IDT with daptomycin at
the same concentration. Acute angioedema
shortly after daptomycin infusion and the
positive IDT result suggested an immediate
hypersensitivity reaction to daptomycin.
Informed consent was obtained from the
patient for being included in this case report.
DISCUSSION
To the best of our knowledge, this is the first
report of angioedema after daptomycin
exposure. A literature review identified only
three published cases of immediate-type
hypersensitivity reactions to daptomycin.
Bagwell et al. [6] reported a 24-year-old
woman with multiple antibiotic allergies. She
had experienced hypersensitivity reactions to
daptomycin previously, and after re-exposure,
pruritus and shortness of breath developed.
Metz and Thyagarajan described a 33-year-old
man who did not tolerate vancomycin because
of a diffuse urticarial eruption [7]. After the
third daptomycin administration, he developed
a generalized urticarial rash (no lip or tongue
swelling or shortness of breath). His symptoms
improved with diphenhydramine, but the
urticarial rash returned after each subsequent
dose. On the basis of the reported patient
history, it is unclear whether this reaction was
IgE mediated or nonspecific (e.g., mast cell
activation). The third case illustrates
desensitization to ceftaroline in a 32-year-old
woman with multiple allergies, including
anaphylaxis to daptomycin (not further
specified) [8]. In contrast to these cases, our
patient had no known allergy, and angioedema
developed acutely after the first dose. In
addition, the association with daptomycin was
suggested by a positive IDT result.
Daptomycin was first approved by the US
Food and Drug Administration (FDA) in
September 2003. After the hallmark study on
daptomycin for S. aureus bacteremia and
endocarditis was published in 2006 [9],
numerous safety data on this agent became
available [3, 10–13]. In addition to known
adverse events (e.g., myotoxicity), an
association of daptomycin with eosinophilic
pneumonia has been raised through an FDA
drug safety communication [1]. Moreover, rare
clinical manifestations such as acute generalized
exanthematous pustulosis and drug rash with
eosinophilia and systemic symptoms have been
reported [14]. Anaphylaxis and angioedema are
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labeled as reactions of unknown frequency and
causality [1, 2]. Worldwide, 72 immediate-type
hypersensitivity reactions to daptomycin have
been reported to WHO pharmacovigilance
centers [15]. In 20 of these cases, the reaction
occurred on the first day of daptomycin
treatment.
In the present case, the more frequently
reported association of beta-lactams with
hypersensitivity reactions [16] and the lack of a
similar case report associated with daptomycin
were misleading. When performing an IDT, a
procedure with sequent dilutions is
recommended (10-4, 10-3, 10-2, 10-1) [17]. We
performed the IDT in the ICU with a 10-1
dilution of the original vial concentration
(50 mg/mL) and all necessary precautions were
taken in case emergency treatment was needed.
As done in our investigations, healthy volunteers
with or without previous exposure to the drug
can be used as negative controls to evaluate
nonspecific skin reaction [17]. Although one
healthy control may be insufficient to draw firm
conclusions, the IDT result and a negative
control was a helpful tool—together with the
clinical observation and detailed time analyses of
drug application—in pointing towards a
daptomycin-associated hypersensitivity
reaction. Because of the clinical circumstances,
no in vitro testing with specific IgE level
measurements to daptomycin could be
performed, and no tryptase was measured.
Although, in our view, IgE-mediated reaction is
likely, it cannot be ascertained. Therefore, the
association with daptomycin is either probable
or certain.
CONCLUSION
Daptomycin is relatively safe and well tolerated.
Serious adverse events are rarely reported.
Nevertheless, clinicians should be aware that
daptomycin can cause immediate-type
hypersensitivity reactions. Our case report
indicates that acute angioedema can be
triggered by daptomycin, even upon first
administration.
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